Abstract Objective: This study aimed to systematically evaluate the clinical efficacy of gabapentin and pregabalin in the treatment of acute herpes zoster (HZ) neuralgia, including pain control and the occurrence of adverse effects. Introduction Herpes zoster (HZ) demonstrates a notable incidence rate of approximately 0.59%–0.77% in individuals aged 50 and above [1–6]. Postherpetic neuralgia (PHN), characterized by pain persisting for at least 90 days after the resolution of the herpes zoster skin rash [7], is a common sequela. Herpes zoster, or shingles, is caused by reactivation of varicella zoster virus, which causes chickenpox. There are an estimated 1 million cases in the Unites States annually, with an individual Abstract Background Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ). Previous trials have reported that gabapentin can relieve chronic neuropathic pain, but its effect on prevention of PHN is unclear. Objective To assess the efficacy of a 5-week course of gabapentin on acute herpetic pain and on the prevention of PHN at 12 weeks in patients with acute HZ The anticonvulsant agent gabapentin is widely prescribed to relieve the chronic pain associated with herpes zoster, but its efficacy during the acute phase of the disease has not been investigated. Herpes zoster (HZ), often called shingles, is a common disease characterized by a painful, unilateral vesicular eruption that is caused by reactivation of a dormant varicella zoster virus within the dorsal root or cranial nerve ganglia. The most frequent complication following an acute episode of HZ infection is postherpetic neuralgia (PHN), a chronic and debilitating neuropathic pain syndrome The recognizable appearance and the dermatomal distribution of herpes zoster lesions usually enable a clinical diagnosis to be made easily. Herpes zoster and postherpetic neuralgia occur mainly in Objective To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster.Design Uncontrolled, open-label study.Setting A private dermatology clinic.Participants Consecutive immunocompetent adults This randomized, double-blind, placebo-controlled crossover study measured the effect of a single dose of oral gabapentin (900 mg) on pain and allodynia associated with herpes zoster. Pain severity decreased by 66% with gabapentin compared to 33% with The herpes zoster vaccine should be used for the primary prevention of herpes zoster and postherpetic neuralgia in persons older than 60 years. The objective of this study is to evaluate the efficacy of treatment with gabapentin in patients with acute herpes zoster for preventing PHN. We performed a prospective randomized controlled study of 120 participants diagnosed with acute herpes zoster, aged 50 and over and complaining moderate to severe pain. What is the efficacy of combination treatment with gabapentin and valacyclovir for the prevention of postherpetic neuralgia in patients with acute herpes zoster? Postherpetic neuralgia (PHN) is a chronic and painful condition that may occur after a herpes zoster infection. The frequency of PHN after untreated zoster varies widely. Age is the most important risk factor for development of PHN. The condition occurs in an estimated 50% of patients older than 50 Gabapentin for postherpetic neuralgia Postherpetic neuralgia³ is a possible lasting consequence of a shingles infection. The condition causes a person to continue feeling the pain associated with blisters and skin lesions even after the skin lesions heal. Although PHN can occur in anyone, it is rare in those under 60 who develop shingles or have severe pain or rash with acute herpes zoster BACKGROUND: Postherpetic neuralgia (PHN) is a common type of neuropathic pain occurring after resolution of herpes zoster rash. Although gabapentin is a widely used treatment, some disagreements exist about its efficacy and safety. Meta-analysis was performed to better evaluate the efficacy and safety of gabapentin for management of PHN. Eligible for inclusion were generally healthy adults with post-herpetic neuralgia of 6 months’ to 5 years’ duration following resolution of the herpes zoster rash and a baseline daily pain intensity score ≥ 4 on an 11-point Likert scale. Abstract Background: Varicella-zoster virus causes chickenpox and can reemerge later in life to cause herpes zoster or shingles. One of the most common and disabling complications of herpes zoster is postherpetic neuralgia (PHN). Conclusion: The results of this study show that gabapentin is effective in acute herpetic neuralgia in different doses with 600 mg/day being the more appropriate dose in terms of safety and efficacy. Keywords: Acute herpetic neuralgia, gabapentin, geriatric patients, herpes zoster, post herpetic neuralgia, visual analogue scale Introduction Background: Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ). Previous trials have reported that gabapentin can relieve chronic neuropathic pain, but its effect on prevention of PHN is unclear. Objective: To assess the efficacy of a 5-week course of gabapentin on acute herpetic pain and on the prevention of PHN at 12 weeks in patients with acute HZ. Methods The objective of this study is to evaluate the efficacy of treatment with gabapentin in patients with acute herpes zoster for preventing PHN. We performed a prospective randomized controlled study of 120 participants diagnosed with acute herpes zoster, aged 50 and over and complaining moderate to severe pain.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |
![]() | ![]() |